Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02563522 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers
A Phase 3 study, sponsored by Helixmith Co..
- Terminated
- Registry status
- Phase 3
- Development phase
- 44
- Enrollment target
NCT02563522 is a Phase 3 study that was terminated before completion, run by Helixmith Co.. The registered enrollment target is 44 participants.
The verdict
NCT02563522, a Phase 3 study, was terminated before completion, sponsored by Helixmith Co..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 44 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of using gene therapy via intramuscular injections of the calf for patients with chronic non-healing foot ulcers.
Interventions
- DRUG Placebo
- GENETIC Engensis (VM202)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2017-06-27 |
| Est. Completion | 2019-09-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02563522
The ClinicalTrials.gov registry entry for NCT02563522 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Helixmith Co., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02563522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02563522 about?
NCT02563522 is a clinical study titled "Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers". This study will assess the safety and efficacy of using gene therapy via intramuscular injections of the calf for patients with chronic non-healing foot ulcers.
What is the current status of trial NCT02563522?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 44 participants. The study started on 2017-06-27. Estimated completion is 2019-09-24.
What interventions are being tested in trial NCT02563522?
The interventions under investigation include: Placebo (DRUG), Engensis (VM202) (GENETIC).
Who is sponsoring clinical trial NCT02563522?
This trial is sponsored by Helixmith Co., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.